福泰制药

个人简介:Dr. Niu has broad experience in clinical & quantitative pharmacology for rare diseases, particularly in viral and non-viral in vivo gene therapy. He is currently the quantitative pharmacology lead for a LNP encapsulated mRNA therapy in cystic fibrosis at Vertex. Prior to Vertex, Tao was the pharmacometrics lead for Wilson’s disease (in vivo replacement gene therapy using AAV) at Pfizer. Dr. Niu also has extensive experience in regulatory submissions and is a key driver in the approval of two drug products (TRIKAFTA® in cystic fibrosis and NGENLA® in pediatric growth hormone deficiency). He is a subject matter expert in biologics PK assay and immunogenicity. He is representing Vertex in the IQ consortium immunogenicity working group. Tao holds a PhD in pharmaceutics from University of Houston, an MS in pharmacometrics from University of Maryland, a BS in pharmaceutical sciences from Shenyang Pharmaceutical University. He is currently working towards a second MS in data science from Georgia Tech. 牛博士在罕见病的临床和定量药理方面具有丰富的经验，特别是病毒和非病毒载体递送的体内基因疗法。他现在是福泰制药囊性纤维化疾病脂质纳米颗粒包裹的信使RNA项目的定量药理代表。在加入福泰制药之前，他曾经是辉瑞制药威尔森疾病腺相关病毒递送的体内基因替代疗法的定量药理代表。牛博士同时在新药报批方面具有丰富的经验。他对于2个新药（囊新纤维化疾病的TRIKAFTA®和儿童生长激素缺乏症的 NGENLA®）的批准做出重大贡献。他是生物药药代动力学分析方法和免疫原性方面的专家。他目前在IQ联盟免疫原性工作小组代表福泰制药。牛韬在美国休斯敦大学获得药剂学博士学位，美国马里兰大学获得药物计量学硕士学位，中国沈阳药科大学获得药学学士学位。他目前正在美国佐治亚理工学院攻读数据科学硕士学位。 查看更多